BIOSYNEX SA: 2025 Half-Year Results and Safeguard Procedure

BIOSYNEX SA has published its 2025 half-year results, marked by a 6% decline in revenue to €50.5 million, due to the strategic refocusing on higher value-added products. Despite a significant improvement in gross operating surplus, now close to breakeven, the company posted a net profit of -€48.6 million, mainly impacted by significant asset impairments.

On September 29, BIOSYNEX initiated safeguard proceedings in an attempt to improve its financial situation. Equity fell to €44.3 million, while net debt stood at €52.3 million. The company is working on a safeguard plan to secure its financial future, all in a difficult economic climate in both France and the United States.